EYE vs. RXST, STAA, WRBY, LUCY, ALC, COO, BLCO, INSP, MMSI, and KRYS
Should you be buying National Vision stock or one of its competitors? The main competitors of National Vision include RxSight (RXST), STAAR Surgical (STAA), Warby Parker (WRBY), Innovative Eyewear (LUCY), Alcon (ALC), Cooper Companies (COO), Bausch + Lomb (BLCO), Inspire Medical Systems (INSP), Merit Medical Systems (MMSI), and Krystal Biotech (KRYS). These companies are all part of the "medical" sector.
National Vision (NASDAQ:EYE) and RxSight (NASDAQ:RXST) are both medical companies, but which is the better stock? We will contrast the two companies based on the strength of their media sentiment, profitability, institutional ownership, valuation, earnings, dividends, community ranking, analyst recommendations and risk.
National Vision currently has a consensus price target of $19.60, indicating a potential upside of 29.89%. RxSight has a consensus price target of $60.63, indicating a potential upside of 3.69%. Given National Vision's higher possible upside, equities analysts plainly believe National Vision is more favorable than RxSight.
RxSight has lower revenue, but higher earnings than National Vision. RxSight is trading at a lower price-to-earnings ratio than National Vision, indicating that it is currently the more affordable of the two stocks.
National Vision has a net margin of -3.44% compared to RxSight's net margin of -44.01%. National Vision's return on equity of 3.47% beat RxSight's return on equity.
National Vision has a beta of 1.47, meaning that its share price is 47% more volatile than the S&P 500. Comparatively, RxSight has a beta of 1.21, meaning that its share price is 21% more volatile than the S&P 500.
National Vision received 217 more outperform votes than RxSight when rated by MarketBeat users. However, 66.67% of users gave RxSight an outperform vote while only 65.89% of users gave National Vision an outperform vote.
78.8% of RxSight shares are held by institutional investors. 2.3% of National Vision shares are held by company insiders. Comparatively, 9.4% of RxSight shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.
In the previous week, National Vision had 9 more articles in the media than RxSight. MarketBeat recorded 13 mentions for National Vision and 4 mentions for RxSight. RxSight's average media sentiment score of 1.56 beat National Vision's score of 0.72 indicating that RxSight is being referred to more favorably in the news media.
Summary
National Vision beats RxSight on 10 of the 18 factors compared between the two stocks.
Get National Vision News Delivered to You Automatically
Sign up to receive the latest news and ratings for EYE and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding EYE and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
National Vision Competitors List
Related Companies and Tools
